Header and Body 2

Problem Addressed

Antibiotic resistant bacteria are an urgent threat to modern medicine. Worldwide there are 30 million new antibiotic-resistant infections diagnosed every year and 5 million of these cases will result in death. Furthermore, the emergence of antibiotic resistant bacteria currently outpaces new drug development, and there is therefore a desperate need to accelerate the rate of antibiotic drug development. Antimicrobial peptides (AMPs) have been proposed as a promising new antibiotic modality. AMPs are small naturally occurring proteins with potent antimicrobial properties; however, most AMPs either display only limited antimicrobial activity or are highly toxic to human cells. The high design cost to develop improved AMPs has thus far limited their use as a therapeutic agent. This technology uses computer-aided design to develop novel AMPs with improved stability, potency, and toxicity profiles.